UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-10315 ______________________________ Encompass Health Corporation (Exact name of Registrant as specified in its Charter) Delaware 63-0860407 (St ...

The Company will award research funding grants totaling up to $50,000. BIRMINGHAM, Ala., May 1, 2024 /PRNewswire/ -- On May 1, Encompass Health opened its call for research grant applications due Sept. 30 at 5 p.m. CST. The grants, totaling up to $50,000, will be awarded for the investigation of the impact or effectiveness of therapies in the inpatient rehabilitation facility post-acute care setting, knowledge translation or implementation science. Grant recipients do not have to be affiliated with Encompas ...

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Encompass Health (EHC) or Chemed (CHE) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks ...

Encompass Health Corporation (EHC) shares lost 0.4% since it reported first-quarter 2024 results on Apr 24. Although it beat estimates thanks to rising patient revenue, strong discharges and a robust pipeline for bed additions. Investors might be concerned regarding elevated operating expenses despite cost control measures undertaken by the company. EHC reported first-quarter 2024 adjusted earnings per share (EPS) of $1.12, which outpaced the Zacks Consensus Estimate by 20.4%. The bottom line rose 27.3% yea ...

Zacks Premium - Zacks Premium提供了多种方式帮助投资者更加聪明和自信地投资[1] Zacks Style Scores - Zacks Style Scores是一组辅助指标，帮助投资者挑选具有在未来30天内击败市场机会的股票[3] 综合分析 - 通过结合Zacks Rank和Style Scores，投资者可以找到具有最有吸引力价值、最佳增长预测和最有前景动量的公司[8]

股价表现 - Encompass Health (EHC) 股价在过去一个月上涨了0.2%，并在前一个交易日达到了新的52周高点，报价为$85.84。[1] - Encompass Health 今年以来股价上涨了24%，远高于Zacks医疗部门的0.8%和Zacks医疗-门诊和家庭保健行业的2.6%。[2] 财务表现 - 公司在过去四个季度中没有错过盈利预期，最近一次财报显示，Encompass Health的每股收益为$1.12，高于预期的$0.93，同时营收也超出预期3.6%。[3] - 预计本财年Encompass Health的每股收益为$4.02，营收为$52.6亿，同比分别增长10.44%和9.51%。明年预计每股收益为$4.50，营收为$57亿，同比增长11.92%和8.33%。[4] 评级和建议 - Encompass Health的价值评分为A，成长和动量评分分别为B和A，综合评分为A。[8] - 公司目前的Zacks排名为2（买入），得益于盈利预期的上升。[10] - 根据Zacks的建议，选择Zacks排名为1（强烈买入）或2（买入）以及价值评分为A或B的股票，Encompass Health符合这些标准，因此在短期内股价可能还有上涨空间。[11]

财务数据和关键指标变化 - 第一季度收入增长13.4%,主要由于总出院量增长10%,其中同店出院量增长6.7% [13][24] - 第一季度调整后EBITDA增长19.2%,主要由于收入增长、劳动力成本趋势稳定以及谨慎的费用管理 [24][25] - 第一季度调整后自由现金流增长5.6%,主要由于调整后EBITDA增加,部分被营运资本增加和更高的现金税款所抵消 [26][27] - 净负债率从年末的2.7倍下降至2.5倍 [27] 各条业务线数据和关键指标变化 - 神经系统和中风患者出院量分别增长10%和12% [116][117] - 脑损伤患者出院量增长11.1% [117] - 其他骨科患者出院量增长近16% [117] - 膝关节和髋关节置换手术患者出院量增长20% [121] 各个市场数据和关键指标变化 - 各地区的出院量增长保持一致,没有明显差异 [30] - Medicare fee-for-service和Medicare Advantage出院量分别增长12%和11%以上 [32] 公司战略和发展方向及行业竞争 - 公司继续投资增加床位容量以满足对住院康复服务的需求,2024年计划新开6家医院共280张床位,并增加93张现有医院床位 [14][15] - 公司持续关注通过部署临床技术和规程来提高患者护理质量和结果,如在88家医院提供内部透析服务 [16] - 公司专注于提高患者满意度和出院准备,推出了"生活质量改善项目" [17] - 公司在阿拉巴马州和宾夕法尼亚州参与了CMS的住院康复设施审查选择示范(RCD),并取得了良好的结果 [18][19] 管理层对经营环境和未来前景的评论 - 公司对需求环境保持乐观,将继续投资增加床位容量以满足需求 [14][21] - 管理层认为,尽管面临劳动力成本压力,但公司有能力通过提高效率和改善招聘来管控成本 [37-44] - 管理层对公司未来的定价和收入增长前景保持谨慎乐观 [65-67] 问答环节重要的提问和回答 问题1 **Kevin Fischbeck 提问** 询问第一季度的出院量情况,包括季度内的变化趋势以及4月份的情况 [28][29][32] **Douglas Coltharp 回答** 出院量在整个季度保持稳定,2月份受益于闰年,3月份受益于复活节假期。季度内各月以及各地区的出院量增长都保持一致 [29][30][32] 问题2 **A.J. Rice 提问** 询问劳动力成本方面的情况,包括永久性工资趋势、临时工薪酬等 [36][37][38][39][40][41][42][44] **Douglas Coltharp 和 Mark Tarr 回答** 总体劳动力成本增长在公司目标范围内,临时工薪酬和合同工使用有所下降,但仍高于疫情前水平。公司持续关注提高招聘和留存,尤其是护理人员 [37-44] 问题3 **Andrew Mok 提问** 询问2024年新开医院的时间节奏 [48][49][50][51][52][53] **Douglas Coltharp 回答** 新开医院主要集中在第2-4季度,第2季度2家,第3季度4家,第4季度可能有1家延后至当季 [50][51][53]

营收表现 - Encompass Health在2024年第一季度报告了132亿美元的营收，同比增长13.4%[1] - 公司的营收超出了Zacks Consensus Estimate的127亿美元，增幅为+3.60%[2] 每股收益 - 每股收益为1.12美元，较去年同期的0.88美元有所增长[1] - 每股收益也超出了预期，增幅为+20.43%[2] 关键指标表现 - Encompass Health在关键指标方面表现良好，如每次出院的患者净收入为20,990美元，超过了分析师平均估计的20,895.64美元[5] - 总出院人数为61,111，超过了两位分析师平均估计的59,601人[5] 收入来源 - 住院康复收入为12.8亿美元，较两位分析师平均估计的12.5亿美元高出[6] - 门诊和其他收入为3,330万美元，较两位分析师平均估计的2,756万美元高出[7] 股票表现 - Encompass Health股票在过去一个月中表现良好，涨幅为+7.5%，目前具有Zacks Rank 2（买入），预示着在短期内可能会跑赢整个市场[8]

Exhibit 99.1 Media Contact April 24, 2024 Kennedi Spurling, 205 970-5912 kennedi.spurling@encompasshealth.com Investor Relations Contact Mark Miller, 205 970-5860 mark.miller@encompasshealth.com Encompass Health reports results for first quarter 2024 Increases full-year guidance BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the first quarter ended March 31, 2 ...

In its upcoming report, Encompass Health (EHC) is predicted by Wall Street analysts to post quarterly earnings of $0.93 per share, reflecting an increase of 5.7% compared to the same period last year. Revenues are forecasted to be $1.27 billion, representing a year-over-year increase of 9.5%. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timef ...